Protumor Activities of the Immune Response: Insights in the Mechanisms of Immunological Shift, Oncotraining, and Oncopromotion

被引:50
作者
Chimal-Ramirez, G. K. [1 ,2 ]
Espinoza-Sanchez, N. A. [1 ,3 ]
Fuentes-Panana, E. M. [1 ]
机构
[1] Inst Mexicano Seguro Social, Hosp Pediat Ctr Med Nacl Siglo 21, UIMEIP, Ave Cuauhtemoc 330, Delegacion Cuauhtemoc 06725, DF, Mexico
[2] IPN, Programa Doctorado Ciencias Quim Biol, Mexico City, DF, Mexico
[3] Univ Autonoma Mexico UNAM, Programa Doctorado Ciencias Biomed, Mexico City, DF, Mexico
关键词
D O I
10.1155/2013/835956
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Experimental and clinical studies indicate that cells of the innate and adaptive immune system have both anti-and pro-tumor activities. This dual role of the immune system has led to a conceptual shift in the role of the immune system's regulation of cancer, in which immune-tumor cell interactions are understood as a dynamic process that comprises at least five phases: immunosurveillance, immunoselection, immunoescape, oncotraining, and oncopromotion. The tumor microenvironment shifts immune cells to perform functions more in tune with the tumor needs (oncotraining); these functions are related to chronic inflammation and tissue remodeling activities. Among them are increased proliferation and survival, increased angiogenesis and vessel permeability, protease secretion, acquisition of migratory mesenchymal characteristics, and self-renewal properties that altogether promote tumor growth andmetastasis (oncopromotion). Important populations in all these pro-tumor processes are M2 macrophages, N2 neutrophils, regulatory T cells, andmyeloid derived suppressor cells; the main effectors molecules are CSF-1, IL-6, metalloproteases, VEGF, PGE-2, TGF-beta, and IL-10. Cancer prognosis correlates with densities and concentrations of protumoral populations and molecules, providing ideal targets for the intelligent design of directed preventive or anticancer therapies.
引用
收藏
页数:16
相关论文
共 175 条
[1]
Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice [J].
Abe, Fuminori ;
Dafferner, Alicia J. ;
Donkor, Moses ;
Westphal, Sherry N. ;
Scholar, Eric M. ;
Solheim, Joyce C. ;
Singh, Rakesh K. ;
Hoke, Traci A. ;
Talmadge, James E. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (01) :47-62
[2]
Eicosanoids in inflammation and cancer: the role of COX-2 [J].
Agarwal, Smita ;
Reddy, Gorla Venkateswara ;
Reddanna, Pallu .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2009, 5 (02) :145-165
[3]
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB [J].
Baldwin, AS .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (03) :241-246
[4]
Cancer-related inflammation: Common themes and therapeutic opportunities [J].
Balkwill, Frances R. ;
Mantovani, Alberto .
SEMINARS IN CANCER BIOLOGY, 2012, 22 (01) :33-40
[5]
Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells [J].
Baratelli, F ;
Lin, Y ;
Zhu, L ;
Yang, SC ;
Heuzé-Vourc'h, N ;
Zeng, G ;
Reckamp, K ;
Dohadwala, M ;
Sharma, S ;
Dubinett, SM .
JOURNAL OF IMMUNOLOGY, 2005, 175 (03) :1483-1490
[6]
Bellocq A, 1998, AM J PATHOL, V152, P83
[7]
Inflammation meets cancer, with NF-κB as the matchmaker [J].
Ben-Neriah, Yinon ;
Karin, Michael .
NATURE IMMUNOLOGY, 2011, 12 (08) :715-723
[8]
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis [J].
Bergers, G ;
Brekken, R ;
McMahon, G ;
Vu, TH ;
Itoh, T ;
Tamaki, K ;
Tanzawa, K ;
Thorpe, P ;
Itohara, S ;
Werb, Z ;
Hanahan, D .
NATURE CELL BIOLOGY, 2000, 2 (10) :737-744
[9]
Bolat F, 2006, J EXP CLIN CANC RES, V25, P365
[10]
BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1